Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors
I'm PortAI, I can summarize articles.
Imugene Limited and JW Therapeutics have announced a strategic collaboration to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene’s onCARlytics oncolytic virus with JW Therapeutics’ Carteyva® CAR-T cell therapy. This initiative includes preclinical studies and a Phase 1 trial in China, aiming to explore new treatment paradigms for solid tumors. The collaboration seeks to generate impactful preclinical and clinical data.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments